Lilly Oncology partners with MDLinx to make new research easily accessible
INDIANAPOLIS, May 31, 2013 -- Recent advancements in cancer research have come at break-neck speed, yielding data that has provided new hope for cancer patients. Each advancement comes with an accompanying manuscript and oncologists are presented, each day, with dozens of newly published peer-reviewed, cancer-related articles in order to keep up to date on the latest advances. To aid physicians and researchers, Eli Lilly and Company (NYSE: LLY) announced an exclusive sponsorship of MDLinx, a web property of M3 USA, for a searchable mobile application that provides reviews of the latest oncology-specific journal articles.
The journal aggregator app, called MDLinx Oncology Articles, is available for Google Android® and Apple iPhone® platforms and allows users to access the oncology information that is most important to them wherever they may be. Physician editors at MDLinx rank, sort and summarize oncology articles from more than 150 oncology journals, allowing oncologists to not only choose what journals they want to follow and filter by sub-specialty, but also search articles by key term or tumor type. The content is selected and controlled exclusively by the MDLinx Editorial Team at M3.
The new app is being launched today at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Ill., to more than 25,000 oncology professionals.
"This sponsorship was an easy decision for Lilly Oncology," said Richard Gaynor, M.D., vice president of product development and medical affairs for Lilly Oncology. "This app offers users the latest updates in the oncology field without having to visit multiple online journal sites. It also allows oncologists to personalize how they get relevant clinical updates which they can apply to their approach with patients in real time."
Similar to other news-source applications, the content is updated daily by MDLinx as new abstracts are published. New content on MDLinx Oncology Articles is ranked by the physician editors based on clinical practice impact and summarized to show the essence of the article. Upon receiving new content, oncologists can also read third-party reviews and recommendations, link to PubMed, and link to the full journal article site. The app also allows users to share abstracts with colleagues.
"We're thrilled to have Lilly Oncology as our exclusive partner for this app," said Aki Tomaru, CEO of M3 USA. "Lilly's commitment to change the world of cancer care fits perfectly with MDLinx's efforts to connect healthcare professionals to the most current medical research for their patients. This application is a great union between the two companies and together we're excited to provide relevant, easy-to-access information to those who need it."
Journal aggregator app available on MDLinx website
Lilly Oncology will provide information about the app to oncologists at their ASCO conference booth, via their sales representatives, and online at www.lillyoncology.com. Directions for downloading the journal aggregator app are also available at www.mdlinx.com/mOncology.
About MDLinx
MDLinx (www.mdlinx.com) is an award-winning, practical medical information tool used by busy physicians and healthcare professionals to stay up to date with the latest research in the medical field. In the US, MDLinx is the #1 specialty physician website and #2 overall physician website. On a daily basis, the company's physician editors summarize, rank and sort published data and research from leading news media and more than 2,000 peer-reviewed journals in 35 specialties and 800 subspecialties. MDLinx's content and services are provided at no charge to member physicians. MDLinx is a property of M3 USA (http://usa.m3.com) which offers information solutions to healthcare providers and industry.
About M3
The M3 Group operates in the US, Asia, and Europe with more than 1 million physician members globally via its physician websites such as www.m3.com, www.mdlinx.com, www.doctors.net.uk, and www.medigate.net. M3, Inc., a publicly traded company on the Tokyo Stock Exchange (JP: 2413) provides services to healthcare and life science industry to reach out to their audience. M3 services include medical education, ethical drug promotion, market research, clinical development, job recruitment, and clinic appointment services. M3 has offices in Tokyo, Washington D.C., Fort Washington, Oxford, London, and Seoul.
About Lilly Oncology
For more than four decades, Lilly Oncology, a division of Eli Lilly and Company, has been dedicated to delivering innovative solutions that improve the care of people living with cancer. Because no two cancer patients are alike, Lilly Oncology is committed to developing novel treatment approaches. To learn more about Lilly's commitment to cancer, please visit www.LillyOncology.com.
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers — through medicines and information — for some of the world's most urgent medical needs.
iPhone is a registered trademark of Apple Inc. and Android is a registered trademark of Google Inc.